Biotechnology - Nanjing Shi, Jiangsu Sheng, China
We consolidated in 2015 from the three entities (Simcere Biologics Group, Novomab, Third Venture);Skilled team (60 - 120 staffs) with global and local biologics and pharma experiences;A pipeline of >10 biologics in clinical and pre-clinical development for oncology and autoimmune diseases;Integrated discovery, development & manufacturing capabilities and facilities in Shanghai and Nanjing;Partnerships for cutting-edge antibody platforms (Vaccinia-based screening platform & bispecific ab).